Newswise — Doctors who treat the painful condition of osteoarthritis in patients with increased cardiovascular risk need to be cautious. A team lead by researchers at Mount Sinai School of Medicine, are the first to study outcomes in high cardiovascular risk patients with osteoarthritis. The researchers compared combination treatments of low-dose aspirin with the drugs ibuprofen, naproxen and the cox-2 inhibitor lumiracoxib. They have found that high cardiovascular risk patients taking ibuprofen and aspirin combined are nine times more likely suffer a heart attack. This new study, published in Annals of the Rheumatic Diseases, suggests that ibuprofen interferes with the blood thinning properties of aspirin in patients at high risk for cardiovascular disease.
Past evidence suggests that both selective cox-2 inhibitors and non-selective non-steroidal anti-inflammatory drugs or NSAIDs increase the risk of cardiovascular events. However, research has been lacking in the high cardiovascular risk population of patients taking aspirin, in-combination with these pain medicines used for osteoarthritis. Mount Sinai researchers are among the first to study this area and have found that the common painkiller ibuprofen used for osteoarthritis, may boost the likelihood of heart problems in high cardiovascular risk patients who are already taking aspirin.
"Ibuprofen has a significantly higher rate of major cardiovascular events, mostly heart attacks, when compared to a COX-2 inhibitor," said Dr. Michael E. Farkouh, M.D., of Mount Sinai Heart, lead investigator of Therapeutic Arthritis Research and Gastrointestinal Event Trial " High Risk (TARGET- HR) and Associate Professor of Medicine and Cardiology at Mount Sinai School of Medicine. "The findings underscore the importance of not only considering the class of NSAIDs used in high risk cardiac patients with osteoarthritis but also making physicians aware of the interaction of NSAIDs with aspirin, diminishing any beneficial effects."
The cardiovascular health of 18, 523 patients over 50 years age with osteoarthritis were compared by researchers in the TARGET trial. Patients were taking high doses of lumiracoxib (Cox-2 inhibitor), or either of the NSAIDs- ibuprofen or naproxen. In patients with osteoarthritis at high cardiovascular risk not taking low-dose aspirin treatment, the rate of heart attacks was higher for those on lumiracoxib than it was for patients on naproxen. It was no higher for patients on ibuprofen. However, in patients at high cardiovascular risk taking low dose aspirin, ibuprofen was associated with a higher incidence of cardiovascular events than lumiracoxib and naproxen. The findings show interference of ibuprofen on the effects of aspirin in high cardiovascular risk patients.
"This is the first randomized trial evidence to show risk of interaction between ibuprofen and aspirin to be real," said Dr. Farkouh. "Doctors should not give high risk cardiovascular patients ibuprofen for pain while they are taking aspirin for their heart. Cardiologists, rheumatologists and gastroenterologists need to work together to fully evaluate the evidence at hand to make proper recommendations to primary care physicians."
Mount Sinai HeartMount Sinai Heart, under the creative leadership of Dr. Valentin Fuster, takes an integrated approach to clinical care, basic research and clinical research to dramatically improve the heart health of individuals globally. Mount Sinai Heart encompasses The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée and Henry R. Kravis Center for Cardiovascular Health at The Mount Sinai Medical Center, preeminent resources for the study and treatment of heart and blood vessel diseases. Committed to finding new and improved methods of diagnosis, treatment and prevention, they comprise a multidisciplinary effort that brings together the expertise of Mount Sinai School of Medicine and The Mount Sinai Hospital in cardiology, cardiovascular surgery, medical education, research and community service, with state-of-the-art facilities for patient care, advanced laboratories for scientific research and leading programs for postgraduate education of clinician-scientists.
About The Mount Sinai Hospital The Mount Sinai Hospital is one of the nation's oldest, largest and most-respected voluntary hospitals. Founded in 1852, Mount Sinai today is a 1,171-bed tertiary-care teaching facility that is internationally acclaimed for excellence in clinical care.
About Mount Sinai School of MedicineLocated in Manhattan, Mount Sinai School of Medicine is internationally recognized for ground-breaking clinical and basic-science research, and innovative approaches to medical education. Through the Mount Sinai Graduate School of Biological Sciences, Mount Sinai trains biomedical researchers with an emphasis on the rapid translation of discoveries of basic research into new techniques for fighting disease. One indication of Mount Sinai's leadership in scientific investigation is its receipt during fiscal year 2005 of $174.1 million in research support from NIH. Mount Sinai School of Medicine also is known for unique educational programs such as the Humanities in Medicine program, which creates opportunities for liberal arts students to pursue medical school, and instructional innovations like The Morchand Center, the nation's largest program teaching students and physicians with "standardized patients" to become not only highly skilled, but compassionate caregivers. Long dedicated to improving its community, the School extends its boundaries to work with East Harlem and surrounding communities to provide access to health care and educational programs to at risk populations.
MEDIA CONTACT
Register for reporter access to contact detailsCITATIONS
Annals of the Rheumatic Diseases
RSS